Miller J, Wynn WH (1908) A malignant tumour arising from the endothelium of the peritoneum, and producing a mucoid ascitic fluid. J Pathol 12(2):267–278. https://doi.org/10.1002/path.1700120212

Article  Google Scholar 

Greenbaum A, Alexander HR (2020) Peritoneal mesothelioma. Transl Lung Cancer Res 9(1):S120–S132. https://doi.org/10.21037/tlcr.2019.12.15

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boffetta P (2007) Epidemiology of peritoneal mesothelioma: a review. Ann Oncol 18(6):985–990. https://doi.org/10.1093/annonc/mdl345

Article  CAS  PubMed  Google Scholar 

Husain AN, Colby TV, Ordóñez NG et al (2017) Guidelines for pathologic diagnosis of malignant mesothelioma: 2017 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. https://doi.org/10.5858/arpa.2017-0124-RA

Article  PubMed  PubMed Central  Google Scholar 

the RENAPE Network, Vogin G, Hettal L et al (2019) Well-differentiated papillary mesothelioma of the peritoneum: a retrospective study from the RENAPE observational registry. Ann Surg Oncol 26(3):852–860. https://doi.org/10.1245/s10434-018-07153-2

Article  Google Scholar 

Nizri E, Baratti D, Guaglio M et al (2018) Multicystic mesothelioma: operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy. Eur J Surg Oncol 44(7):1100–1104. https://doi.org/10.1016/j.ejso.2018.03.004

Article  PubMed  Google Scholar 

Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP (1980) Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 68(3):356–362

Article  CAS  PubMed  Google Scholar 

Berghmans T, Paesmans M, Lalami Y et al (2002) Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 38(2):111–121

Article  CAS  PubMed  Google Scholar 

Jänne PA, Wozniak AJ, Belani CP et al (2005) Open-label study of pemetrexed alone or in combination with cisplatin for the treatment of patients with peritoneal mesothelioma: outcomes of an expanded access program. Clin Lung Cancer 7(1):40–46. https://doi.org/10.3816/CLC.2005.n.020

Article  PubMed  Google Scholar 

Carteni G, Manegold C, Garcia GM et al (2009) Malignant peritoneal mesothelioma-results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent. Lung Cancer 64(2):211–218. https://doi.org/10.1016/j.lungcan.2008.08.013

Article  CAS  PubMed  Google Scholar 

Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636–2644. https://doi.org/10.1200/JCO.2003.11.136

Article  CAS  PubMed  Google Scholar 

Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27(36):6237–6242. https://doi.org/10.1200/JCO.2009.23.9640

Article  PubMed  Google Scholar 

Helm JH, Miura JT, Glenn JA et al (2014) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg Oncol. https://doi.org/10.1245/s10434-014-3978-x

Article  PubMed  Google Scholar 

Verma V, Sleightholm RL, Rusthoven CG et al (2018) Malignant peritoneal mesothelioma: national practice patterns, outcomes, and predictors of survival. Ann Surg Oncol 25(7):2018–2026. https://doi.org/10.1245/s10434-018-6499-1

Article  PubMed  Google Scholar 

Bijelic L, Darcy K, Stodghill J, Tian C, Cannon T (2020) Predictors and outcomes of surgery in peritoneal mesothelioma: an analysis of 2000 patients from the National Cancer Database. Ann Surg Oncol 39(7):576–579. https://doi.org/10.1245/s10434-019-08138-5

Article  Google Scholar 

Yan TD, Deraco M, Elias D et al (2011) A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer 117(9):1855–1863. https://doi.org/10.1002/cncr.25640

Article  PubMed  Google Scholar 

Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M (2016) The role of Ki-67 and pre-cytoreduction parameters in selecting diffuse malignant peritoneal mesothelioma (DMPM) patients for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 23(5):1468–1473. https://doi.org/10.1245/s10434-015-4962-9

Article  PubMed  Google Scholar 

Alexander HR, Bartlett DL, Pingpank JF et al (2013) Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153(6):779–786. https://doi.org/10.1016/j.surg.2013.01.001

Article  PubMed  Google Scholar 

Ceelen WP, Flessner MF (2010) Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 7(2):108–115. https://doi.org/10.1038/nrclinonc.2009.217

Article  PubMed  Google Scholar 

Turaga KK, Deraco M, Alexander HR (2017) Current management strategies for peritoneal mesothelioma. Int J Hyperthermia 33(5):579–581. https://doi.org/10.1080/02656736.2017.1320591

Article  PubMed  Google Scholar 

Sugarbaker PH, Chang D (2017) Long-term regional chemotherapy for patients with epithelial malignant peritoneal mesothelioma results in improved survival. Eur J Surg Oncol 43(7):1228–1235. https://doi.org/10.1016/j.ejso.2017.01.009

Article  CAS  PubMed  Google Scholar 

Le Roy F, Gelli M, Hollebecque A et al (2017) Conversion to complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma after bidirectional chemotherapy. Ann Surg Oncol 24(12):3640–3646. https://doi.org/10.1245/s10434-017-6033-x

Article  PubMed  Google Scholar 

Giger-Pabst U, Demtröder C, Falkenstein TA et al (2018) Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for the treatment of malignant mesothelioma. BMC Cancer 18(1):442. https://doi.org/10.1186/s12885-018-4363-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jacquet P, Sugarbaker PH (1996) Peritoneal-plasma barrier. In: Peritoneal Carcinomatosis: Principles of Management. Vol 82. Cancer Treatment and Research. Boston, MA: Springer, Boston, MA;53–63. https://doi.org/10.1007/978-1-4613-1247-5_4.

Dedrick RL, Myers CE, Bungay PM, DeVita VT (1978) Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 62(1):1–11

CAS  PubMed  Google Scholar 

Dedrick RL (1985) Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol 12(3 Suppl 4):1–6

CAS  PubMed  Google Scholar 

Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J (1980) Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 40(2):256–260

CAS  PubMed  Google Scholar 

Yan TD, Welch L, Black D, Sugarbaker PH (2007) A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 18(5):827–834. https://doi.org/10.1093/annonc/mdl428

Article  CAS  PubMed  Google Scholar 

Ma GY, Bartlett DL, Reed E et al (1997) Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am 3(3):174–179

CAS  PubMed  Google Scholar 

Lemoine L, Sugarbaker P, Van Der Speeten K (2017) Drugs, doses, and durations of intraperitoneal chemotherapy: standardising HIPEC and EPIC for colorectal, appendiceal, gastric, ovarian peritoneal surface malignancies and peritoneal mesothelioma. Int J Hyperth 33(5):582–592. https://doi.org/10.1080/02656736.2017.1291999

Article  CAS  Google Scholar 

Kusamura S, Kepenekian V, Villeneuve L et al (2020) Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2020.02.011

Article  PubMed  Google Scholar 

Chicago Consensus Working Group (2020) The Chicago consensus on peritoneal surface malignancies: management of peritoneal mesothelioma. Ann Surg Oncol 19(1):1–6. https://doi.org/10.1245/s10434-020-08324-w

Article  Google Scholar 

Latin American Registry of Peritoneal Diseases – LARPD participants (2018) Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Eur J Surg Oncol 44(11):1800–1804. https://doi.org/10.1016/j.ejso.2018.06.029

Article  Google Scholar 

Batista TP, Sarmento BJQ, Loureiro JF et al (2017) A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma. Rev Col Bras Cir 44(5):530–544. https://doi.org/10.1590/0100-69912017005016

Article  PubMed  Google Scholar 

Li Y, Zhou Y-F, Liang H et al (2016) Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol 22(30):6906–6916. https://doi.org/10.3748/wjg.v22.i30.6906

Article  PubMed  PubMed Central  Google Scholar 

Lurvink RJ, Villeneuve L, Govaerts K et al (2019) The Delphi and GRADE methodology used in the PSOGI 2018 consensus statement on pseudomyxoma peritonei and peritoneal mesothelioma. Eur J Surg Oncol. https://doi.org/10.1016/j.ejso.2019.03.012

Article  PubMed  Google Scholar 

Chicago Consensus Working Group (2020) The Chicago consensus on peritoneal surface malignancies: methodology. Ann Surg Oncol 1–2. https://doi.org/10.1245/s10434-020-08317-9.

Guyatt GH, Oxman AD, Kunz R et al (2008) Going from evidence to recommendations. BMJ 336(7652):1049–1051. https://doi.org/10.1136/bmj.39493.646875.AE

Article  PubMed  PubMed Central  Google Scholar 

Malgras B, Gayat E, Aoun O et al (2018) Impact of combination chemotherapy in peritoneal mesothelioma hyperthermic intraperitoneal chemotherapy (HIPEC): the RENAPE study. Ann Surg Oncol 25(11):3271–3279. https://doi.org/10.1245/s10434-018-6631-2

Article  PubMed  Google Scholar 

Yurttas C, Hoffmann G, Tolios A et al (2018) Systematic review of variations in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastasis from colorectal can